CCDC183-AS1: A Potential Drug Target and Biomarker (G100131193)

Target Name: CCDC183-AS1

NCBI ID: G100131193

Other Name(s): KIAA1984-AS1 | RP11-216L13.8 | CCDC183 antisense RNA 1

CCDC183-AS1: A Potential Drug Target and Biomarker

CDC183-AS1, also known as CSF1, is a protein that is expressed in the cerebellum, which is the part of the brain responsible for motor coordination and balance. It has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

CDC183-AS1: Structure and Function

CDC183-AS1 is a transmembrane protein that is expressed in the cerebellum and is involved in the development and maintenance of normal cerebellum structure and function. It is a member of the Tetraspan gene family, which includes proteins that are involved in the regulation of cell-cell interactions, including those between cells and the extracellular matrix (ECM).

CDC183-AS1 is involved in the development and maintenance of the normal structure of the cerebellum, including the development of new neurons and the maintenance of the integrity of existing neurons. It is also involved in the regulation of the movement of neurons, which is critical for normal motor function.

CDC183-AS1: Potential Drug Target

CDC183-AS1 has been identified as a potential drug target for various neurological and psychiatric disorders due to its involvement in the regulation of normal brain function. One of the main targets of CDC183-AS1 is the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In Alzheimer's disease, the accumulation of toxic beta-amyloid peptides is thought to contribute to the destruction of brain cells and the development of the disease. CDC183-AS1 has been shown to regulate the production of beta-amyloid peptides and has been shown to be involved in the protective effects against beta-amyloid peptide-induced neurotoxicity.

In addition to its potential role in the development of neurodegenerative disorders, CDC183-AS1 may also be a useful biomarker for these disorders. The loss of normal cerebellum structure and function is a common feature of neurodegenerative disorders, and changes in the expression of CDC183-AS1 may provide insight into the severity and progression of these disorders.

CDC183-AS1: Potential Biomarker

CDC183-AS1 has also been identified as a potential biomarker for various neurological and psychiatric disorders. The loss of normal cerebellum structure and function is a common feature of many neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

CDC183-AS1 may be used as a biomarker for these disorders by measuring the expression of its gene in the cerebellum. The expression of CDC183-AS1 may be affected by the presence of various neurological and psychiatric disorders, and changes in its expression may provide insight into the severity and progression of these disorders.

Conclusion

In conclusion, CDC183-AS1 is a protein that is expressed in the cerebellum and is involved in the development and maintenance of normal cerebellum structure and function. It has been identified as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease and Parkinson's disease. It may also be a useful biomarker for these disorders by measuring the expression of its gene in the cerebellum. Further research is needed to fully understand the role of CDC183-AS1 in the development and treatment of neurodegenerative disorders.

Protein Name: CCDC183 Antisense RNA 1

More Common Targets